Gastric adenocarcinoma can be divided into intestinal and diffuse, according to Lauren’s classification. Pathological aspects were discussed previously regarding this grouping. The same was done with respect to the biological behavior of these tumors, with diffuse adenocarcinoma presenting a more aggressive behavior comparing to the intestinal type. Essentially, such behavior is the major impact factor in surgical treatment, especially in endoscopic management. Regardless of its classification, the curative treatment of gastric cancer necessarily involves endoscopic resection or surgery even with the several options of neoadjuvant and adjuvant treatment that are available. This chapter describes the surgical management of diffuse gastric cancer, an aggressive disease, and its peculiarities.
KeywordsGastric cancer Surgical treatment Diffuse type Endoscopic resection Resection margin Lymphadenectomy
- 3.Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, Chung DC, Norton J, Ragunath K, Van Krieken JH, Dwerryhouse S, Caldas C, International Gastric Cancer Linkage C. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet. 2010;47:436–44.CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Anold D, on behalf of the ESMO Guidelines Committe. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2016;27(Supplement 5):v38–49. https://doi.org/10.1093/annonc/mdw350.CrossRefPubMedGoogle Scholar
- 9.Marrelli D, Pedrazzani C, Morgagni P, de Manzoni G, Pacelli F, Coniglio A, et al. Italian Research Group for Gastric Cancer. Changing clinical and pathological features of gastric cancer over time. Br J Surg. 2011;98:1273–83.Google Scholar
- 12.Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, Bereder JM, Lorimier G, Quenet F, Elias D. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:2370–7.CrossRefPubMedGoogle Scholar
- 20.Moehler M, Baltin CTH, Ebert M, Fischbach W, Gockel I, Grenacher L, et al. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer. 2015;18:550–63.CrossRefPubMedGoogle Scholar